This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Breast Cancer Recurrent
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
-
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States, 84112
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
University of Utah,
Christos Vaklavas, MD, PRINCIPAL_INVESTIGATOR, Huntsman Cancer Institute
2027-09-30